Copenhagen Stock Exchange:NOVO B - Ireland News Beep

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Read More

Evoke phase 3 trials did not demonstrate

November 24, 2025

Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of…

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Read More

Novo Nordisk’s sales increased by 12% in Danish kroner and

November 5, 2025

Bagsværd, 5 November, 2025 – Financial report for the period 1 January 2025 to 30 September 2025 …

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Read More

Novo Nordisk and Omeros announce asset purchase and license

October 15, 2025

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…